Publications
187
Citations
4,706
Est. group size
~12
Recurring co-author estimate
Active years
39
Publishing since 1988
Ginny L. Bumgardner's research focuses on the immune system's role in organ transplant rejection, particularly how antibodies produced by the body's B cells attack transplanted kidneys and livers. A major focus is a specialized type of white blood cell called CXCR5+CD8+ T cells, which appear to suppress harmful antibody responses after transplantation, along with studies of Epstein-Barr virus-related lymphoma treatment. This work combines laboratory mouse models with clinical and surgical training topics relevant to transplant surgery.
Publication output increased notably from 2020 to 2022, dipped in 2023, then stabilized at a moderate pace through 2024-2026, averaging under 4 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease
Blood Neoplasia · 2026
- The American Society of Transplant Surgeons and American Journal of Transplantation at 25 years: Where we have been and where we will go
American Journal of Transplantation · 2026
- Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5+CD8+ T Cells
Transplantation Direct · 2025
- Mouse Models and Experimental Protocols to Study Alloantibody‐Mediated Transplant Rejection
Current Protocols · 2025
- An Entrustable Professional Activity for Research in Surgical Residency Training
Annals of Surgery · 2025
- Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells
The Journal of Immunology · 2024
- Roadmap for Research and Scholarship in General Surgery Residency Training
Annals of Surgery · 2024
- Abstract LB422: Specific activation of the Epstein-Barr Virus <i>BGLF4</i> locus via lowered DNA methylation in EBV-associated CNS lymphoproliferative disease
Cancer Research · 2024
- Epigenetic Activation of the EBV Protein Kinase Determines Antiviral Drug Response in Central Nervous System Lymphoma
medRxiv · 2024
- CXCR5+CD8+ T Cell–mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition
Transplantation · 2023
- Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease
Blood · 2023
- Antibody-suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice
American Journal of Transplantation · 2022
- Facilitating Success of the Early Stage Surgeon Scientist Trainee: Growing the Surgeon Scientist Pipeline.
PubMed · 2022
- Alloprimed antibody-suppressor CD8+ T cells preferentially kill alloprimed germinal center B cells
The Journal of Immunology · 2022
- Deficiency of antibody-suppressor CXCR5+CD8+ T cells (not CD4+ Tregs) drives high alloantibody production in CCR5 KO kidney transplant recipients
The Journal of Immunology · 2022
- The Journal of Immunology×11
- Transplantation×6
- American Journal of Transplantation×3
- Annals of Surgery×3
- Clinical Transplantation×3
- Mark D. Pescovitz
Medicine · Indiana University
- John A. Powelson
Medicine · Indiana University
- Elmahdi Elkhammas
Medicine · The Ohio State University
- Farjad Siddiqui
Medicine · The Ohio State University
- Todd E. Pesavento
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile